UWM will cover lender-paid 1-0 buydowns on eligible purchase loans through 06/30/2026 and adds home equity loans.
America’s rewiring of the international security apparatus has shown Europe’s ability to act decisively. EU member states have introduced ...
The Phase 3 clinical trial to explore the safety and efficacy of UGN-104 is ongoing and is expected to be fully enrolled by the end of 2026. UGN-104 is a next-generation mitomycin product for LG-UTUC.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results